List of Excipients in Branded Drug CHILDRENS ADVIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	CHILDRENS ADVIL	ibuprofen	0573-0174	CARBOXYMETHYLCELLULOSE SODIUM
Haleon US Holdings LLC	CHILDRENS ADVIL	ibuprofen	0573-0174	CELLULOSE, MICROCRYSTALLINE
Haleon US Holdings LLC	CHILDRENS ADVIL	ibuprofen	0573-0174	CITRIC ACID MONOHYDRATE
Haleon US Holdings LLC	CHILDRENS ADVIL	ibuprofen	0573-0174	EDETATE DISODIUM

Children’s Advil Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

Children’s Advil is an over-the-counter ibuprofen product positioned for pediatric pain and fever relief. Its commercial value depends less on active-ingredient exclusivity than on formulation performance, dosing accuracy, taste, caregiver convenience, channel placement, and brand trust. The principal excipient opportunities are palatability, suspension stability, preservative systems, sugar reduction, dye-free positioning, and delivery-device design.

What is Children’s Advil and how is it regulated?

Children’s Advil is marketed in the United States as an oral ibuprofen product for children. A standard liquid formulation contains ibuprofen at 100 mg per 5 mL, equivalent to 20 mg/mL. The product is regulated as an OTC analgesic and antipyretic under the FDA’s ibuprofen monograph framework rather than through a new drug application for each commercial formulation.[1]

Attribute	Children’s Advil
Active ingredient	Ibuprofen
Typical liquid strength	100 mg per 5 mL
Therapeutic class	Nonsteroidal anti-inflammatory drug
Primary uses	Temporary relief of fever and minor aches and pains
Regulatory route	OTC monograph
Primary dosage form	Oral suspension or liquid
U.S. brand owner	Haleon plc and related operating entities
Prescription status	Nonprescription
Orange Book status	Generally not applicable to monograph OTC products
Pediatric positioning	Children, with age and dosing restrictions on labeling

The product’s labeling, dosage instructions, warnings, and inactive ingredients must comply with applicable FDA requirements. Ibuprofen products must also carry age-related warnings, dosing instructions, and contraindications, including warnings concerning stomach bleeding, allergic reactions, and use in children recovering from chickenpox or influenza-like illness.[1,2]

Which Children’s Advil formulation is relevant to excipient analysis?

The exact inactive-ingredient profile depends on the product variant, flavor, dosage form, package, and market. Public labeling for pediatric ibuprofen suspensions commonly identifies excipients such as:

• Purified water
• Glycerin
• Sucrose or other sweeteners
• Xanthan gum or another suspending agent
• Polysorbate 80 or another wetting agent
• Citric acid and sodium citrate
• Sodium benzoate or another preservative
• Flavoring agents
• Color additives in selected variants

The commercial analysis should treat each SKU as a separate formulation opportunity. Grape, berry, orange, dye-free, sugar-free, and combination products can have different excipient systems even when they use the same ibuprofen concentration.

What excipients are most important in Children’s Advil?

The highest-value excipients are those that improve dose uniformity, palatability, physical stability, and caregiver acceptance without increasing regulatory or manufacturing complexity.

Suspending agents

Ibuprofen has low aqueous solubility. A liquid pediatric product therefore depends on a suspension system that keeps particles evenly distributed after shaking and supports accurate dosing throughout the bottle.

Xanthan gum is commercially attractive because it provides strong suspension performance at relatively low concentration and remains effective across a broad pH range. Its drawbacks include possible stringiness, high viscosity, and mouthfeel that some children reject.

Other candidate polymers include:

• Microcrystalline cellulose and carboxymethylcellulose combinations
• Sodium carboxymethylcellulose
• Hydroxyethylcellulose
• Poloxamers
• Pregelatinized starches
• Acrylic or cellulosic rheology modifiers

The development target is not maximum viscosity. It is controlled sedimentation with rapid redispersion, acceptable pourability, and a low risk of dose stratification. Excessive viscosity can reduce dosing accuracy when a caregiver uses a syringe or dosing cup.

Wetting and dispersing agents

Wetting agents help ibuprofen particles disperse in the aqueous vehicle. Polysorbate 80 is widely used in oral formulations, but its level must be controlled because excess surfactant can affect taste, foaming, and gastrointestinal tolerance.

Alternative approaches include particle-size reduction, surface treatment, improved milling, or polymeric dispersants. These approaches can reduce dependence on surfactants but may increase equipment requirements and process controls.

Sweeteners and flavor systems

Taste is a central commercial variable. Ibuprofen has a bitter, persistent taste that can be difficult to mask in pediatric liquids. Sucrose provides sweetness and contributes to mouthfeel, but it raises concerns about dental exposure, caloric content, and suitability for sugar-conscious households.

Potential alternatives include:

• Sucralose
• Acesulfame potassium
• Saccharin sodium
• Sorbitol
• Xylitol
• Maltitol
• Steviol glycosides
• High-intensity flavor systems combined with bitterness blockers

A sugar-free formulation can support premium positioning, but polyols can create gastrointestinal tolerance issues and may change viscosity and preservative performance. A high-intensity sweetener system can reduce solids content, but it may produce aftertaste and require a more complex flavor architecture.

Buffers and pH control

Citric acid and sodium citrate are commonly used to control pH and improve flavor balance. The pH affects preservative efficacy, ibuprofen stability, polymer performance, and sensory properties.

The optimal pH range must balance several competing objectives:

1. Chemical stability of ibuprofen and the excipient system.
2. Preservative effectiveness.
3. Reduced irritation and acceptable oral sensation.
4. Consistent viscosity during shelf life.
5. Compatibility with flavor and color components.

A formulation with a narrow pH operating range creates manufacturing risk. Robust buffer capacity can improve batch consistency but may increase flavor impact.

Preservatives

Multidose pediatric liquids require protection against microbial growth. Sodium benzoate is a common option in acidic oral liquids. Potassium sorbate and other systems may also be considered, subject to pH and compatibility requirements.

Preservative selection is commercially sensitive because parents increasingly examine inactive ingredients. A “clean label” formulation may seek to reduce or eliminate traditional preservatives, but that strategy requires strong microbial-control evidence, packaging controls, and validated in-use stability.

Colors and dyes

Color can support flavor recognition and brand differentiation. It can also create a market barrier for children whose caregivers avoid artificial dyes. A dye-free product can command a premium or expand distribution into retailers with ingredient-screening policies.

The most practical strategy is often a portfolio approach:

• Standard flavored product with color
• Dye-free product with natural or no added color
• Sugar-free product
• Higher-concentration product for older children, if permitted and clearly labeled

Each variant increases supply-chain and inventory complexity. The portfolio must justify the additional SKU burden through incremental sales or higher margin.

What formulation patents protect Children’s Advil?

Children’s Advil does not have the same patent structure as a recently approved prescription drug. A monograph OTC product generally does not receive new chemical entity exclusivity, pediatric exclusivity, or an Orange Book-based period of market protection.

Protection category	Relevance to Children’s Advil
New chemical entity exclusivity	Not applicable to longstanding ibuprofen
OTC monograph compliance	Primary regulatory pathway
Orange Book listing	Generally not applicable
Paragraph IV litigation	Not typically applicable to monograph OTC competition
Pediatric exclusivity	No product-specific period expected
Formulation patents	Possible, but claims must be independently verified
Trademark protection	Important for Advil and product branding
Trade secrets	Potentially important for flavor, process, and supplier specifications
Device protection	Possible for dosing syringes, caps, and child-resistant packages

The strongest defensible assets are likely to be brand trademarks, formulation know-how, manufacturing controls, flavor systems, packaging design, and consumer recognition rather than broad ibuprofen composition claims.

A company developing a competing product could pursue formulation patents covering a specific combination of particle size, suspending polymer, sweetener, flavor, preservative, pH, or redispersibility profile. Such patents would face validity and obviousness challenges because pediatric ibuprofen suspensions are established dosage forms.

When does Children’s Advil lose exclusivity?

Children’s Advil does not have a conventional patent cliff comparable to a patented prescription medicine. Its commercial exclusivity is based primarily on brand equity, retail access, shelf placement, formulation differentiation, and consumer trust.

Generic and private-label pediatric ibuprofen products can enter under the applicable OTC regulatory framework if they comply with FDA requirements. The practical competitive risk is therefore continuous rather than concentrated on a single patent expiration date.

What is the Orange Book status of Children’s Advil?

Children’s Advil is generally not an Orange Book-protected product in the same way as an approved prescription drug with listed patents and regulatory exclusivity. Competitors do not normally need to file a Paragraph IV certification against a Children’s Advil Orange Book patent to launch a comparable monograph product.

Are there Paragraph IV challenges to Children’s Advil?

Paragraph IV challenges are generally not the central entry mechanism for a monograph OTC ibuprofen product. Competition is more likely to arise through:

• Private-label ibuprofen suspensions
• Store-brand pediatric fever reducers
• Authorized generic or contract-manufactured products
• New flavor and delivery formats
• E-commerce brands
• Combination products, where permitted by FDA labeling rules

What commercial opportunities exist in Children’s Advil excipients?

How can a sugar-free formulation create value?

Sugar-free positioning can appeal to caregivers seeking lower-sugar products and retailers with healthier-product criteria. The main technical challenge is maintaining acceptable taste without excessive polyol loading or a lingering artificial-sweetener profile.

The opportunity is strongest when sugar reduction is paired with:

• A well-performing bitterness blocker
• A recognizable flavor
• A clear “no added sugar” or equivalent compliant claim
• A dosing syringe rather than a cup
• Packaging that communicates age-specific dosing simply

Can dye-free Children’s Advil capture market share?

Dye-free products can compete for households that avoid artificial colors. The opportunity is more commercial than therapeutic. It depends on broad distribution, clear labeling, and maintaining a familiar flavor identity without relying on color cues.

A dye-free line may also reduce exposure to retailer restrictions on synthetic colors. The tradeoff is higher formulation and packaging complexity if the product requires separate flavor, bottle, label, and inventory systems.

What role can dosing devices play?

A dosing syringe is a high-value adjunct to the liquid formulation. It can improve dosing accuracy, reduce caregiver confusion, and support infant and young-child use where a cup is less practical.

Device-related opportunities include:

• Syringes with age or weight graduations
• Flow restrictors
• One-way bottle adapters
• Child-resistant closure systems
• Low-residue bottle designs
• Integrated dose-tracking caps
• Unit-dose sachets for travel

A device can create differentiation that is difficult for low-cost competitors to replicate quickly. It also introduces human-factors, packaging, compatibility, and regulatory validation requirements.

Can higher concentration improve the product?

A higher concentration can reduce dose volume for older children, but it creates medication-error risk if caregivers confuse strengths. Any concentration change requires prominent labeling, compatible dosing devices, and careful assessment of accidental overdose scenarios.

A single widely recognized concentration can be commercially safer than a multiproduct portfolio unless the company has strong packaging controls and marketing discipline.

How strong is the Children’s Advil patent estate?

The patent estate is likely weaker than the brand estate. Ibuprofen is an old active ingredient, and conventional pediatric suspensions use established excipient categories. Broad claims covering ibuprofen, water, a sweetener, a suspending agent, and a flavor would face substantial prior-art exposure.

Potentially stronger claim areas include:

1. A narrowly defined particle-size distribution.
2. A specific rheology profile that improves dose uniformity.
3. A preservative-free multidose system with validated microbial protection.
4. A novel bitterness-masking combination.
5. A package-and-formulation combination that reduces dosing error.
6. A manufacturing process that limits aggregation or improves redispersion.
7. A stable dye-free flavor system with defined shelf-life performance.

Trade-secret protection may be more valuable than patent protection for flavor ratios, raw-material specifications, process order, mixing energy, homogenization conditions, and quality-control limits.

What generic entry risks exist for Children’s Advil?

Generic entry risk is high because ibuprofen is widely available, the active ingredient is inexpensive, and pediatric suspension technology is established. The main barriers are commercial, not molecule-specific.

Risk factor	Competitive impact
Low active-ingredient cost	Supports aggressive private-label pricing
Established suspension technology	Reduces development barriers
OTC monograph pathway	Avoids traditional prescription approval hurdles
Brand recognition	Protects Advil’s premium position
Retailer private labels	Increases price pressure
Flavor and palatability	Creates room for differentiation
Dosing-device quality	Can support premium pricing
Supply-chain scale	Favors major manufacturers
Product recalls	Can quickly damage consumer trust

A generic launch would most likely begin with a conventional 100 mg/5 mL suspension, followed by dye-free, sugar-free, berry, grape, or travel-oriented variants. The strongest defense is a differentiated product architecture supported by reliable supply, superior taste, accurate dosing, and retailer coverage.

Which companies compete with Children’s Advil?

Children’s Advil competes primarily with:

• Children’s Tylenol, containing acetaminophen
• Store-brand children’s ibuprofen
• Store-brand acetaminophen products
• Motrin-related pediatric products
• Pediatric fever reducers sold through pharmacies, supermarkets, warehouse clubs, and e-commerce platforms

Advil and Tylenol differ in active ingredient, dosing restrictions, contraindications, and caregiver perception. Ibuprofen products can benefit from positioning around fever and pain relief, while acetaminophen products have broader familiarity among some caregivers. Neither positioning eliminates the need for precise pediatric dosing communication.

What is the revenue exposure for Haleon?

Haleon reports performance at a portfolio and category level rather than disclosing revenue for every Children’s Advil SKU. Product-specific revenue, margin, and geographic contribution therefore cannot be inferred reliably from public company reporting.[3]

The commercial exposure is still material at the brand-system level because Children’s Advil supports:

• Pediatric analgesic shelf presence
• Cross-selling with adult Advil products
• Seasonal fever-reducer demand
• Pharmacy and mass-retail distribution
• E-commerce search visibility
• Brand retention among family households

The product is exposed to seasonality, retailer promotion, raw-material costs, recalls, formulation changes, and shifts between branded and store-brand purchasing.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are process control and sensory performance. A technically compliant product can still fail commercially if it settles rapidly, pours inconsistently, tastes bitter, foams, stains, leaks, or produces inaccurate doses.

Key controls include:

• Ibuprofen particle-size distribution
• Wetting and deagglomeration
• Mixing sequence
• Polymer hydration
• Viscosity and yield stress
• pH control
• Preservative assay
• Microbial limits
• Redispersibility after storage
• Dose uniformity across bottle life
• Closure and dosing-device compatibility

The most valuable IP may be a package of process know-how and sensory optimization rather than a single blocking patent. A competitor can copy the broad excipient categories while still struggling to reproduce the same mouthfeel, stability, and manufacturing yield.

Key Takeaways

• Children’s Advil is primarily an OTC monograph ibuprofen product, not a conventional patent-protected prescription drug.
• The commercial formulation opportunity centers on taste masking, suspension stability, sugar reduction, dye-free positioning, and dosing-device performance.
• Generic and private-label entry risk is high because ibuprofen and pediatric suspension technology are established.
• Orange Book exclusivity and Paragraph IV litigation are generally not central to this product category.
• Narrow formulation patents may be possible, but trade secrets and trademarks are likely more durable commercial assets.
• The most attractive innovation areas are bitterness blockers, low-volume dosing, preservative optimization, dye-free systems, and child-resistant packaging.
• Haleon’s public reporting does not isolate Children’s Advil revenue, so product-level revenue exposure cannot be quantified from disclosed company data.

FAQs

Is Children’s Advil a suspension or a solution?

The standard liquid product is an oral suspension because ibuprofen has limited water solubility. The formulation requires wetting, particle dispersion, and viscosity control.

Can a competitor patent a new Children’s Advil flavor?

A flavor alone is usually a weak patent position. A patent may be stronger if the flavor is part of a defined formulation that improves bitterness masking, stability, redispersibility, or dose uniformity.

Does dye-free Children’s Advil have regulatory exclusivity?

No. Dye-free positioning does not create regulatory exclusivity. It can create commercial differentiation and support premium pricing.

What is the largest excipient risk in pediatric ibuprofen?

The largest technical risk is dose nonuniformity caused by sedimentation, aggregation, or inadequate redispersion. The largest commercial risk is poor taste that reduces adherence and repeat purchase.

Is a preservative-free Children’s Advil formulation commercially viable?

It may be viable with suitable packaging and validated microbial protection, but a multidose aqueous product requires rigorous in-use and microbiological controls. A preservative-free claim can create consumer value while increasing manufacturing and validation costs.

References

1. U.S. Food and Drug Administration. (2023). Ibuprofen oral drug products for over-the-counter human use. 21 C.F.R. § 343.80. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343

2. U.S. Food and Drug Administration. (2022). Drug facts label requirements. https://www.fda.gov/drugs/understanding-over-counter-medicines/over-counter-drug-facts-label

3. Haleon plc. (2024). Annual report and financial statements 2023. https://www Haleon.com/investors/results-reports-and-events/annual-reports.html